Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Efficacy and Safety Study of mXELIRI Versus. FOLFIRI + Bevacizumab Therapy as First-line Chemotherapy in Metastatic Colorectal Cancer

NCT04247984 is registered in ClinicalTrials.gov with Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT04247984
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04247984 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Efficacy and Safety Study of mXELIRI Versus. FOLFIRI + Bevacizumab Therapy as First-line Chemotherapy in Metastatic Colorectal Cancer
Lead sponsor
Chinese Academy of Medical Sciences
Phase
Phase 2
Overall status
Completed
Start date
May 1, 2018
Completion date
January 31, 2022
Enrollment
264 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer